NCT05573789

Tumor Molecular Profiling in Patients With Prostate Cancer

Investigation of Mutations in DNA Damage Repair Genes and Other Actionable Molecular Aberrations as Biomarkers in Patients With Prostate Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 220 (actual)
• Sponsor: Hellenic Cooperative Oncology Group · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer. Patients with histologically confirmed prostate cancer, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments, were included. The presence of gene alterations was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic.

Detailed description

Data on tumor molecular profiling of European patients with prostate cancer is limited. The aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer. Patients with histologically confirmed prostate cancer, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments, were included. The presence of gene alterations was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic. The primary endpoint was the prevalence of gene alterations in homologous recombination repair (HRR) genes. Secondary endpoint was overall survival.

Conditions

• Prostate Cancer
• Metastatic Prostate Adenocarcinoma

Interventions

Type	Name	Description
GENETIC	Tumor molecular profiling	Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic

Timeline

• Start date: 2018-01-01
• Primary completion: 2020-12-31
• Completion: 2022-09-01
• First posted: 2022-10-10
• Last updated: 2022-10-19

Locations

1 site across 1 country: Greece